The Question Behind Every Result
When a lab report says you carry a CYP2D6 variant or a BRCA1 pathogenic mutation, a reasonable person asks: how does the lab actually know? The honest answer is that "genetic testing" is not one technology — it is several, with different physics, different error profiles, and different best uses. Two tests with identical-looking reports can rest on wildly different methodological foundations. As the scientist responsible for our laboratory's analytical pipeline, I want to explain the three dominant technologies, why we built Gene Matrix panels on the Agena MassArray platform, and what you should ask any lab before trusting a result.
The Three Technologies, Honestly Compared
| Technology | How It Works | Strengths | Limits | Best Use |
|---|---|---|---|---|
| Agena MassArray (MALDI-TOF mass spectrometry) | Target DNA variants are amplified, then each allele is weighed directly by mass spectrometry — a physical measurement, not a fluorescent inference. | Extremely high analytical accuracy on targeted variants; high call rates; fast; cost-effective for defined panels; excellent for PGx star alleles and known pathogenic variants. | Targeted by design — measures the variants on the panel, not the whole genome. | Clinical panels answering defined questions: pharmacogenomics, hereditary cancer hotspots, carrier screening targets. |
| Next-generation sequencing (NGS) | Millions of DNA fragments are read in parallel and stitched back to a reference genome. | Broad discovery — can find novel variants across exomes or genomes; the right tool when the target is unknown. | Coverage gaps and depth variability; short reads struggle with pseudogenes (e.g., CYP2D6 vs CYP2D7) without specialized pipelines; higher cost and slower turnaround. | Exome/genome diagnostics, tumor profiling, rare-disease discovery. |
| SNP microarray (consumer chips) | Fluorescent probes report which allele is present at pre-selected positions — typically a few hundred thousand genome-wide. | Cheap, massive scale; adequate for ancestry and common-trait statistics. | Genotypes a sparse, fixed set of common SNPs; misses rare pathogenic variants; notorious false-positive rates on rare-variant calls without confirmation; most consumer reports are labeled not for medical use. | Ancestry, trait exploration, research cohorts — not clinical decisions. |
None of these is "best" in the abstract. The methodological question is always: does the technology match the clinical question? Sequencing your whole genome to answer "what dose of escitalopram?" is like commissioning a satellite survey to find your car keys — impressive, expensive, and slower than looking in the right drawer.
Analytical Validity Is the Foundation
Two words separate rigorous labs from marketing: analytical validity — does the test measure what it claims, reproducibly? — and clinical validity — does that measurement predict the health outcome? Analytical validity comes first, and it is where methodology matters most.
Analytical accuracy of our CLIA-validated panels — verified against reference materials and confirmed by repeat testing before release.
The international medical-laboratory quality standard our lab operates under, alongside CLIA certification (ID 14D2276402) and CAP accreditation.
Dual review — every clinical report is verified by automated QC and then signed off by a second qualified reviewer before release.
MALDI-TOF mass spectrometry earns its place here because it is a direct physical measurement. The MassArray does not ask a camera to interpret a glow; it weighs the allele. For the known, clinically actionable variants that make up a PGx or hereditary cancer panel, that yields analytical accuracy up to 99.9% with very high first-pass call rates — the numbers a physician can dose against.
Why We Use MassArray for Panels
Gene Matrix tests answer defined clinical questions: does this patient metabolize clopidogrel? Does this family carry a Lynch syndrome variant? Those questions have known answers at known genomic addresses, which is precisely the problem class targeted mass spectrometry was built for. Our 230+-gene PGx panel and 108-gene cancer panel are designed variant-by-variant against CPIC, FDA, and NCCN-referenced targets, CLIA-validated as complete assays, and run with positive and negative controls on every batch. Where a result warrants it — an unusual pattern, a borderline call — reflex confirmation by a second method is standard practice.
Dual Review: Two Sets of Eyes on Every Report
Technology is only half of accuracy; process is the other half. Every Gene Matrix result passes automated quality control (call-rate thresholds, control performance, contamination checks), then human review: a laboratory scientist verifies the analytical run, and a qualified reviewer — under our Lab Director's sign-off — confirms the clinical interpretation against current guidelines. A report does not leave the lab until both reviews are complete. This is the same dual-verification discipline hospital laboratories use, applied to direct-access testing.
What to Ask Any Lab Before You Test
- What technology generates the result? If a consumer chip report claims rare pathogenic variants, ask whether they were confirmed by a second, clinical-grade method.
- Is the lab CLIA-certified, and is the assay CLIA-validated? Certification covers the lab; validation covers the specific test.
- What is the analytical accuracy, and against which reference standards? Vague answers here are a red flag.
- Who reviews the report before release? Look for named laboratory-director oversight and dual review.
- What happens at the boundaries? Ask how the lab handles low-quality samples, novel variants, and variants of uncertain significance.
What This Means For You
You should not need a mass-spectrometry degree to trust your DNA test — but you deserve a lab that has one. Gene Matrix runs targeted MassArray panels validated for clinical use, in a CLIA-certified, CAP-accredited, ISO 15189 laboratory, at up to 99.9% analytical accuracy, with dual review on every report. Results in 5–7 days (48-hour priority available). See the full methodology on our science page, browse the GenePGx panel, or check the genetics glossary for plain-English definitions of every term in this article.
FAQs
They answer different questions. For known, clinically actionable variants — PGx star alleles, hereditary cancer targets — MALDI-TOF mass spectrometry delivers up to 99.9% analytical accuracy at lower cost and faster turnaround. NGS is the right tool for broad discovery, like exome sequencing for undiagnosed rare disease.
A method that weighs DNA molecules directly. After target amplification, allele-specific products are vaporized by laser and timed through a flight tube — their mass reveals which variant you carry. It is a physical measurement rather than a fluorescent inference, which is why it achieves very high analytical accuracy on targeted panels.
For ancestry and common traits they are generally fine. The documented weakness is rare pathogenic variants, where unconfirmed chip results show high false-positive rates in published studies — one reason most consumer reports are labeled not for medical use, and clinical labs confirm before reporting.
Ask for the assay's analytical validation data, the lab's certifications (CLIA, CAP, ISO 15189), and who signs the report. Gene Matrix tests are CLIA-validated, run with batch controls, dual-reviewed, and released under our Lab Director & Medical Director's oversight.
